Venus Medtech (Hangzhou) Inc. (“Venus Medtech”), is the leader in transcatheter structural heart valvular therapies in China. The company is committed to the development and commercialization of innovative medical devices in the field of structural heart disease. Venus Medtech is founded in 2009 and headquartered in Hangzhou National High-Tech Industrial Development Zone (Binjiang). On December 10th, 2019, the company was successfully listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2500.HK).
Venus Medtech has established comprehensive solutions for structural heart disease, with a complete product pipeline covering all four heart valves, namely TAVR, TPVR, TMVR and TTVR, as well as hypertrophic cardiomyopathy, hypertensive renal denervation (RDN) therapy and relevant accessory products.
Moving Forward, Venus Medtech will focus on new materials, bionics, image fusion techniques and digital sensing for continuous upgrades and innovation, meeting the needs of doctors and patients worldwide. Moreover, the company will continue efforts to develop and commercialize novel structural heart devices, supporting China’s rise as an innovation powerhouse and contributing to the well-being of global communities.